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BACKGROUND
Early exposure to complex dietary proteins may increase the risk of beta-cell auto-
immunity and type 1 diabetes in children with genetic susceptibility. We tested the 
hypothesis that supplementing breast milk with highly hydrolyzed milk formula 
would decrease the cumulative incidence of diabetes-associated autoantibodies in 
such children.
METHODS
In this double-blind, randomized trial, we assigned 230 infants with HLA-conferred 
susceptibility to type 1 diabetes and at least one family member with type 1 diabetes 
to receive either a casein hydrolysate formula or a conventional, cow’s-milk–based 
formula (control) whenever breast milk was not available during the first 6 to 8 months 
of life. Autoantibodies to insulin, glutamic acid decarboxylase (GAD), the insulinoma-
associated 2 molecule (IA-2), and zinc transporter 8 were analyzed with the use of 
radiobinding assays, and islet-cell antibodies were analyzed with the use of immuno-
fluorescence, during a median observation period of 10 years (mean, 7.5). The 
children were monitored for incident type 1 diabetes until they were 10 years of age.
RESULTS
The unadjusted hazard ratio for positivity for one or more autoantibodies in the 
casein hydrolysate group, as compared with the control group, was 0.54 (95% con-
fidence interval [CI], 0.29 to 0.95), and the hazard ratio adjusted for an observed 
difference in the duration of exposure to the study formula was 0.51 (95% CI, 0.28 to 
0.91). The unadjusted hazard ratio for positivity for two or more autoantibodies was 
0.52 (95% CI, 0.21 to 1.17), and the adjusted hazard ratio was 0.47 (95% CI, 0.19 to 
1.07). The rate of reported adverse events was similar in the two groups.
CONCLUSIONS
Dietary intervention during infancy appears to have a long-lasting effect on markers 
of beta-cell autoimmunity — markers that may reflect an autoimmune process leading 
to type 1 diabetes. (Funded by the European Commission and others; ClinicalTrials.gov 
number, NCT00570102.)
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T ype 1 diabetes is defined by the loss of insulin-producing beta cells in the pan-creatic islets in genetically susceptible per-
sons. Overt diabetes is preceded by an asymptom-
atic period of highly variable duration1 during 
which diabetes-associated autoantibodies appear 
in the peripheral circulation as markers of emerg-
ing beta-cell autoimmunity. Five disease-related 
autoantibodies predict the clinical manifestation 
of type 1 diabetes: islet-cell antibodies; insulin 
autoantibodies; and autoantibodies to glutamic 
acid decarboxylase (GAD), the tyrosine phospha-
tase-related insulinoma-associated 2 molecule 
(IA-2), and zinc transporter 8 (ZnT8).2,3 Positivity 
for two or more antibodies signals a risk of 50 to 
100% for the development of type 1 diabetes over 
the course of 5 to 10 years.4
Accumulating evidence suggests that beta-cell 
autoimmunity may be induced early in life.5,6 The 
incidence of type 1 diabetes is rising faster than 
it had previously among children, particularly 
among children younger than 5 years of age.7,8 
Food content in early childhood may modify the 
risk of type 1 diabetes later in life. A short dura-
tion of breast-feeding and early exposure to com-
plex dietary proteins have been implicated as 
risk factors for advanced beta-cell autoimmunity 
or clinical type 1 diabetes.9,10 Early nutritional 
intervention may help to prevent type 1 diabetes 
and has been reported to be successful in experi-
mental models of autoimmune diabetes, although 
the data are not consistent.11-14 Our preliminary 
data indicated that among children at increased 
risk for type 1 diabetes, weaning to a highly 
hydrolyzed formula decreased the cumulative in-
cidence of islet-cell antibodies and the cumula-
tive incidence of at least one autoantibody during 
a mean observation period of 4.7 years.15 In this 
article, we report findings from the pilot study 
of the Trial to Reduce IDDM in the Genetically 
at Risk (TRIGR), which documents the rates of 
beta-cell autoimmunity and progression to clini-
cal diabetes in children up to 10 years of age.
Me thods
Study Design
We conducted a randomized, double-blind study 
at 15 hospitals in Finland. Newborn infants who 
had a first-degree relative with type 1 diabetes 
were recruited between February 1995 and No-
vember 1997. Written informed consent was ob-
tained from the mothers before enrollment. The 
protocol that was initially approved by the ethics 
committee at each participating hospital called 
for observation of the children until they reached 
2 years of age; it was subsequently modified to 
allow for observation of the children until they 
reached 10 years of age. The protocol, including 
the statistical analysis plan, is available with the 
full text of this article at NEJM.org. An agreement 
that the results would remain confidential until 
publication was in force between the members of 
the TRIGR Study Group and Mead Johnson Nutri-
tion, which provided the study formulas. Mead 
Johnson Nutrition had no role in the design of the 
study, the accrual or analysis of the data, or the 
preparation of the manuscript. The first author 
wrote the initial draft of the manuscript; all the 
authors contributed to the final version of the 
manuscript and vouch for the accuracy and com-
pleteness of the reported data, as well as the fi-
delity of the report to the trial protocol.
Study Participants
Over the course of 34 months, we identified 520 
newborn infants for possible inclusion in the 
study. A total of 45 did not meet the inclusion 
criteria, mainly owing to prematurity (gestational 
age of <36 weeks) or the unavailability of a cord-
blood sample for HLA genotyping. Altogether, 
475 newborn infants received a study code at 
birth, and HLA genotypes were obtained for 470, 
usually within 1 week after birth; 230 newborn 
infants with an eligible HLA risk genotype (49% 
of the infants for whom HLA genotypes were ob-
tained) continued in the intervention study (Fig. 
1), of whom 131 (57%) were boys. A total of 85 
infants (37%) had a mother with type 1 diabetes, 
100 (43%) had an affected father, 35 (15%) had 
an affected sibling, and 10 (4%) had more than 
one affected first-degree relative.
Autoantibody Data
Blood samples were obtained (after application 
of analgesic cream) at the follow-up visits when 
the children were 3, 6, 9, 12, 18, and 24 months 
of age and thereafter when they were 3, 5, 7, and 
10 years of age. Serum samples were stored at 
–70°C until they could be analyzed. Autoantibody 
data were obtained from 208 children (90%) who 
had at least one follow-up sample available. The 
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mean follow-up time for the detection of auto-
antibodies was 7.5 years (median, 10 years; range, 
3 months to 10 years).
Dietary Intervention
Infants were randomly assigned after birth to re-
ceive either the intervention formula or a control 
formula whenever breast milk was not available. 
The intervention formula was an extensively hydro-
lyzed casein-based formula (Nutramigen, Mead 
Johnson Nutrition); the control formula, which 
was produced specifically for this study, was com-
posed of 80% intact milk protein (Enfamil) and 
20% hydrolyzed milk protein and was formulated 
so that the taste and smell would be indistin-
guishable from those of the intervention formula. 
Study formulas were prepared and coded with 
the use of four colors by Mead Johnson Nutrition, 
which held the codes. Newborn infants requiring 
supplemental feeding before randomization (e.g., 
infants born at night or on weekends) received 
banked breast milk or Nutramigen. The codes, 
which were broken, as specified by the protocol, 
when the youngest child in the study completed 
the intervention, revealed that 113 infants had 
been randomly assigned to the casein hydrolysate 
group and 117 to the control group. There were 
no differences in the distribution of HLA geno-
types or of affected family members between the 
two groups (Table 1 in the Supplementary Appen-
dix, available at NEJM.org).
Breast-feeding was practiced at the discretion 
of the participating mothers, and maternal diets 
were unmodified. Breast-feeding was encouraged 
and exceeded national averages in both study 
groups. The dietary intervention period lasted 
until the infant was at least 6 months of age. If 
the mother chose to breast-feed exclusively until 
the child was 6 months of age, the opportunity to 
use the study formula was extended for 2 months, 
until the child was 8 months of age. Parents were 
told not to feed the children any commercial 
230 Were eligible and underwent randomization
470 Newborn infants were screened for HLA
risk genotype
240 Were excluded on the basis
of their HLA genotype
113 Were assigned to be weaned
to a highly hydrolyzed formula
117 Were assigned to be weaned to
a regular cow’s-milk–based formula
14 Were withdrawn
without providing any
follow-up samples
99 Provided at least
one follow-up sample
3 Had incident diabetes
Were assigned to receive
xxx
0 Had incident diabetes
109 Provided at least
one follow-up sample
8 Were withdrawn
without providing any
follow-up samples
1 Had incident diabetes
17 Had ≥2 auto-
antibodies detected
8 Had incident diabetes
8 Had ≥2 auto-
antibodies detected
4 Had incident diabetes
Figure 1. Screening, Randomization, and Follow-up.
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baby foods and other foods containing bovine 
protein during the intervention period. Adherence 
to the protocol was monitored by means of regu-
lar family interviews and by analysis of cow’s-milk 
antibodies in serum samples.
HLA Genotyping
An analysis of cord-blood HLA-DQB1 genotype was 
performed to identify selected alleles (DQB1*02, 
*0301, *0302, and *0602/3) that are known to be 
significantly associated with susceptibility to or 
protection against type 1 diabetes.16 In DQB1*02-
positive infants, the DQA1 allele was also ana-
lyzed. The genotyping technique is based on 
solution hybridization with lanthanide-labeled 
oligonucleotide probes detected with the use of 
time-resolved fluorometry.17 Infants were eligi-
ble for the trial if they carried the high-risk HLA-
DQB1*02/DQB1*0302 genotype (51 infants [22%]), 
the moderate-risk DQB1*0302/x genotype (x ≠ 
DQB1*0301, *0602, or *0603) (92 infants [40%]), 
or the HLA-DQA1*05-DQB1*02(DR3)/y genotype 
(y ≠ DQB1*0301, *0602, or *0603) (87 infants 
[38%]), which, although it confers an increased 
risk of disease, confers a risk lower than that 
with the other genotypes.
Detection of Beta-Cell Autoimmunity
Islet-cell antibodies were detected with the use of 
indirect immunofluorescence, whereas the other 
four autoantibodies were quantified with the use 
of specific radiobinding assays.18 We used cutoff 
limits for positivity of 2.5 Juvenile Diabetes Foun-
dation (JDF) units for islet-cell antibodies, 3.48 
relative units (RU) for insulin autoantibodies, 
5.36 RU for GAD autoantibodies, 0.43 RU for 
IA-2 autoantibodies, and 0.61 RU for ZnT8 auto-
antibodies. The disease sensitivity and specificity 
of the assay for islet-cell antibodies were 100% 
and 98%, respectively, in the fourth round of the 
international workshops on standardization of 
the ICA assay. The disease sensitivity and speci-
ficity of the assay for insulin autoantibodies were 
58% and 100%, respectively, in the 2005 Diabetes 
Antibody Standardization Program (DASP) work-
shop. The corresponding characteristics of the 
assay for GAD autoantibodies were 82% and 
96%, and those of the assay for IA-2 autoantibod-
ies were 72% and 100%. The assay for ZnT8 auto-
antibodies had a sensitivity of 50% and a specific-
ity of 100% in the 2009 DASP workshop. Maternal 
antibodies that were transferred through the pla-
centa, as verified by detectable autoantibodies in a 
maternal blood sample, were not included in the 
statistical analysis.
Progression to Type 1 Diabetes
Progression to type 1 diabetes was recorded, al-
though it was not the primary end point of the 
study. The information about incident diabetes 
was obtained mainly from the pediatric clinics at 
which the children were followed. In addition, as a 
secondary source, the incidence of diabetes in the 
entire cohort was confirmed by means of infor-
mation obtained from a national drug reimburse-
ment registry that includes data from virtually 
the entire population of Finland.19
Statistical Analysis
The differences between the two groups with re-
spect to the autoantibody titers and the duration 
of exposure to the study formula were assessed 
with the use of the Mann–Whitney U test. In the 
case of a child who was positive for antibodies, 
seroconversion was considered to have occurred 
sometime between the last time a negative test 
was obtained and the time of the first positive 
measurement (an interval-censored survival time). 
If a child had only negative measurements, no 
seroconversion was assumed to have occurred 
before the last measurement (a right-censored 
survival time). A nonparametric survival analysis 
was performed with the use of the self-consistency 
algorithm of Turnbull20 to obtain maximum-
likelihood estimates of the survival functions of 
seroconversion to positivity for diabetes-predic-
tive autoantibodies during the follow-up period. 
The hazard ratios associated with exposure to 
the formula were estimated with the use of flex-
ible parametric models, in which restricted cubic 
splines are used to smooth the baseline log cumu-
lative hazard.21
Cox proportional-hazards regression was used 
to analyze the association between the interven-
tion and the risk of clinical type 1 diabetes. The 
analyses were adjusted for the duration of expo-
sure to the formula and for the child’s age at the 
time the formula was introduced. Both of these 
variables were treated as time-dependent co-
variates and were used as continuous variables. 
Whenever both were included in the model, the 
interaction between duration and age was al-
lowed. The likelihood functions of the regression 
models were based on interval-censored survival 
times and were maximized with the use of the 
Broyden–Fletcher–Goldfarb–Shanno (BFGS) algo-
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rithm of the “optim” function in the R statistical 
package.22 The interval package in R was used to 
calculate the nonparametric maximum-likelihood 
estimates of the survival functions.
The intention-to-treat principle was used for 
the analyses of seroconversion to autoantibody 
positivity and progression to type 1 diabetes. The 
analysis of progression to type 1 diabetes was 
also performed according to treatment received 
(per-protocol analysis). All tests were two-tailed; 
P values of less than 0.05 were considered to 
indicate statistical significance.
R esult s
Study Intervention
The median age of the infants at the time the 
study formula was introduced was 2.6 months in 
the casein hydrolysate group and 1.1 months in 
the control group (P = 0.03). The median age at 
the time the intervention was completed was 7.4 
months in the casein hydrolysate group and 6.4 
months in the control group (P = 0.15). The me-
dian duration of study-formula feeding was 3.3 
months in the casein hydrolysate group and 4.9 
months in the control group (P = 0.05).
Beta-Cell Autoimmunity
A total of 208 children (90%) — 99 in the casein 
hydrolysate group and 109 in the control group 
— provided at least one blood sample during the 
follow-up period for determination of diabetes-
associated autoantibodies. At least one autoanti-
body developed in 17 of the children in the casein 
hydrolysate group (17%) and 33 in the control 
group (30%). Eight children in the casein hydro-
lysate group (8%), as compared with 17 in the con-
trol group (16%), tested positive for two or more 
autoantibodies; data from each of these children 
on sex, genotype, and the autoantibodies that de-
veloped, as well as the age of the children at the 
time they developed, are provided in Table 2 in the 
Supplementary Appendix. Insulin autoantibodies 
were the first or among the first antibodies that 
appeared in children in whom multiple autoanti-
bodies were already detectable in the first posi-
tive sample (15 of the 25 children with multiple 
autoantibodies [60%]). Islet-cell antibodies were 
also the first or among the first antibodies that 
appeared (15 of 25 children [60%]), whereas 5 chil-
dren (20%) tested positive for IA-2 autoantibod-
ies and only 1 child (4%) tested positive for ZnT8 
autoantibodies in the first autoantibody-positive 
sample.
The earliest age at which autoantibodies were 
detected was 6 months (Patient 26 in Table 2 in 
the Supplementary Appendix), and the latest sero-
conversion was observed when the child was 10 
years of age. Among the children who tested 
positive for autoantibodies, there were no signifi-
cant between-group differences in the initial or 
maximal autoantibody titers (data not shown). 
The cumulative incidences of islet-cell antibodies, 
insulin autoantibodies, and IA-2 autoantibodies 
in the casein hydrolysate group and in the control 
group, according to the age of the children at the 
time the autoantibodies were detected, are shown 
as nonparametric maximum-likelihood estimates 
in Figure 2. The cumulative incidences of at least 
one autoantibody and of at least two autoanti-
bodies in the two groups are shown in Figure 3. 
Between-group comparisons of the cumulative 
incidence of GAD autoantibodies and ZnT8 auto-
antibodies are provided in Figure 1 in the Supple-
mentary Appendix.
The results of the analysis of hazard ratios 
are shown in Table 1. Feeding with the casein 
hydrolysate formula was associated with a de-
crease in the risk of seroconversion to positivity 
for islet-cell antibodies, IA-2 autoantibodies, and 
at least one autoantibody (one or more of islet-
cell antibodies, insulin autoantibodies, GAD auto-
antibodies, IA-2 autoantibodies, and ZnT8 auto-
antibodies). As noted above, there was a difference 
between the two groups in the duration of expo-
sure to the study formula. After adjustment for 
this variable, a significant protective effect of the 
intervention against positivity for islet-cell anti-
bodies, IA-2 autoantibodies, and at least one auto-
antibody was noted, whereas there was a trend 
for a protective effect against positivity for at least 
two autoantibodies (Table 1). Further adjustments 
for the age at introduction of the study formula 
or for both age at introduction and duration of 
exposure to the study formula resulted in no 
changes or only minor changes in the hazard 
ratios (Table 3 in the Supplementary Appendix).
Progression to Overt Diabetes
Type 1 diabetes developed in 16 children (7%) by 
the time they were 10 years of age — 7 of the 113 
children in the casein hydrolysate group (6%) and 
9 of the 117 children in the control group (8%). 
The mean age at diagnosis was 4.8 years (range, 
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0.8 to 9.6). The risk for type 1 diabetes was not 
significantly associated with the feeding interven-
tion (hazard ratio with casein hydrolysate, 0.80; 
95% confidence interval [CI], 0.30 to 2.14). The 
hazard ratio adjusted for the difference in the 
duration of exposure to the study formula was 
0.48 (95% CI, 0.14 to 1.61). Three children in 
whom overt type 1 diabetes developed dropped 
out of the study before the age of 3 months — 
two within 2 to 4 days after birth and the third 
just before the 3-month follow-up visit. All three 
children had been randomly assigned to the ca-
sein hydrolysate group, but none had received any 
study formula. Their diagnostic information was 
obtained from the Finnish Social Insurance Reg-
istry. Accordingly, the number of children in the 
per-protocol cohort (i.e., the cohort defined ac-
cording to the treatment received) who pro-
gressed to type 1 diabetes was four in the casein 
hydrolysate group (4%) and nine in the control 
group (8%). In the per-protocol cohort, the hazard 
ratio for type 1 diabetes with casein hydrolysate 
was 0.40 (95% CI, 0.11 to 1.51). Of the 13 children 
in the per-protocol cohort in whom diabetes de-
veloped, all but 1 (Patient 26 in Table 2 in the 
Supplementary Appendix) had samples that tested 
positive for multiple autoantibodies in the preclin-
ical period. The child who did not test positive in 
the preclinical period was positive for insulin auto-
antibodies in a sample obtained at the age of 
6 months (the last available sample for that infant) 
— 14 months before the clinical presentation.
Adverse Events
The rate of reported adverse events was similar in 
the two groups. Details of the adverse events that 
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Figure 2. Cumulative Incidence of Islet-Cell Antibodies, 
Insulin Autoantibodies, and Autoantibodies to the Insu-
linoma-Associated 2 Molecule (IA-2) in the Two Study 
Groups.
The cumulative incidence of islet-cell antibodies (Panel A), 
insulin autoantibodies (Panel B), and IA-2 autoantibodies 
(Panel C) in the casein hydrolysate group and in the 
control group, according to the age of the children at 
the time the autoantibodies were detected, is shown, 
with the use of nonparametric maximum-likelihood es-
timates (black) and fitted curves (blue) of the regression 
models. For the nonparametric maximum-likelihood es-
timates, gray rectangles show the intervals within which 
any curve would maximize the likelihood. The P values 
are derived from analyses adjusted for the duration of 
exposure to the study formula.
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were reported are provided, according to study 
group, in Table 4 in the Supplementary Appendix.
Discussion
Our study showed that among children with an 
HLA genotype conferring increased risk for type 1 
diabetes and a first-degree relative with type 1 
diabetes, weaning to a highly hydrolyzed formula 
during infancy was associated with fewer signs 
of beta-cell autoimmunity up to 10 years of age. 
Our study was not powered for any definitive 
conclusion concerning progression to overt type 1 
diabetes, but a larger TRIGR study now ongoing 
in 15 countries on three continents is designed 
with adequate power to address that issue.23
Preliminary data from our trial, case–control 
studies,24 and observations from studies in non-
obese diabetic mice11 and BioBreeding rats12 
suggest that complex foreign-protein diets dur-
ing weaning may play a deleterious role in the 
process leading to autoimmune diabetes. In the 
control group in our study, the cumulative inci-
dence of multiple autoantibodies by the age of 
6 years was 12% (derived from data in Table 2 in 
the Supplementary Appendix), and the cumula-
tive incidence of type 1 diabetes by the age of 10 
years was 8%.
Our data suggest that weaning to a highly hy-
drolyzed formula, as compared with a cow’s-milk–
based formula, was associated with a decreased 
risk of positivity for at least one diabetes-associ-
ated autoantibody, as reflected by an unadjusted 
hazard ratio with the highly hydrolyzed formula 
of 0.54 and by a hazard ratio after adjustment 
for the difference in the duration of exposure to 
the study formula of 0.51. The corresponding 
hazard ratios for multiple (≥2) autoantibodies 
were 0.52 and 0.47. The observed decrease in the 
risk of positivity for GAD autoantibodies was 
smaller than that for the other autoantibodies, a 
finding that is not surprising given that, in con-
trast to the other autoantibodies, GAD autoanti-
bodies have been shown to be associated with a 
low risk for progression to type 1 diabetes among 
young children with HLA-defined disease suscep-
tibility.25 The mechanisms by which hydrolyzed 
formula decreases the risk of diabetes-predictive 
autoantibodies are not known. We speculate that 
potential mechanisms may involve reduced gut 
permeability, induction of the maturation of reg-
ulatory T cells in the gut-associated lymphoid 
tissue, modification of the gut microflora, or 
some combination of these. A recent study showed 
that highly hydrolyzed formula was associated 
with a decrease in autoimmune diabetes in the 
disease-prone BioBreeding rat, in association with 
improved integrity of the intestinal barrier and 
production of regulatory cytokines, as well as 
beneficial changes in gut microflora.26
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Figure 3. Cumulative Incidences of at Least One Autoantibody and of at Least 
Two Autoantibodies.
The cumulative incidences of at least one autoantibody (Panel A) and at least 
two autoantibodies (Panel B) in the casein hydrolysate group and in the con-
trol group, according to the age of the children at the time the autoantibodies 
were detected, are shown, with the use of nonparametric maximum-likeli-
hood estimates (black) and fitted curves (blue) of the regression models. 
For the nonparametric maximum-likelihood estimates, gray rectangles show 
the intervals within which any curve would maximize the likelihood. The P val-
ues are derived from analyses adjusted for the duration of exposure to the 
study formula.
The New England Journal of Medicine 
Downloaded from nejm.org at TAMPERE UNIVERSITY LIBRARY on June 19, 2013. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Dietary Intervention in Infancy and Beta-Cell Autoimmunity
n engl j med 363;20 nejm.org november 11, 2010 1907
Our study was not designed to test the effect 
of breast-feeding, since randomly assigning in-
fants to breast-feeding or formula feeding would 
not be ethical. Some prospective studies assess-
ing the associations between infant feeding pat-
terns and the development of beta-cell autoim-
munity in children who are at genetic risk for 
type 1 diabetes have not detected any associations 
between the duration of either exclusive or total 
breast-feeding and beta-cell autoimmunity.27-29 
However, a single-cohort study involving children 
in the general population showed that a short 
duration of breast-feeding was related to an in-
creased risk of positivity for GAD autoantibodies, 
insulin autoantibodies, or both.30
Our results indicate that a preventive dietary 
intervention aimed at decreasing the risk of type 
1 diabetes may be feasible. Such an intervention 
would need to be initiated early in life, since the 
first signs of beta-cell autoimmunity may appear 
before a child reaches the age of 3 months.6 If 
such an intervention is shown to be effective and 
safe in high-risk children, a next step might be 
to expand the intervention to a wider infant 
population, since 83 to 98% of children with 
newly diagnosed type 1 diabetes are from the 
general population.31 Nutritional intervention dur-
ing infancy, such as that provided in this study, 
may be an attractive strategy, since it could be 
implemented relatively easily as a public health 
measure.
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Table 1. Hazard Ratios with Highly Hydrolyzed Infant Formula, as Compared with Conventional Cow’s-Milk–Based 
Formula, for Seroconversion to Positivity for Autoantibodies Predictive of Type 1 Diabetes.*
Autoantibodies
No. Who 
Underwent 
Seroconversion
Hazard Ratio 
with Highly 
Hydrolyzed 
Formula 
(95% CI) P Value
Adjusted Hazard 
Ratio with Highly 
Hydrolyzed Formula
(95% CI)† P Value
Islet-cell antibodies 37 0.38 (0.18–0.77) 0.006 0.37 (0.17–0.75) 0.005
Insulin autoantibodies 23 0.72 (0.30–1.64) 0.45 0.61 (0.25–1.42) 0.26
GAD autoantibodies 23 0.87 (0.37–1.97) 0.74 0.80 (0.34–1.85) 0.61
IA-2 autoantibodies 20 0.36 (0.12–0.94) 0.04 0.32 (0.10–0.83) 0.02
ZnT8 autoantibodies 14 0.61 (0.19–1.77) 0.37 0.61 (0.19–1.79) 0.37
≥1 Antibody 50 0.54 (0.29–0.95) 0.03 0.51 (0.28–0.91) 0.02
≥2 Antibodies 25 0.52 (0.21–1.17) 0.12 0.47 (0.19–1.07) 0.07
* A total of 208 children (90% of the 230 participants who continued in the pilot trial after HLA genotyping) had a mini-
mum of one serum sample available for autoantibody testing: 99 in the group that was randomly assigned to receive 
the hydrolyzed formula and 109 in the group that received the cow’s-milk–based formula. GAD denotes glutamic acid 
decarboxylase, IA-2 insulinoma-associated 2 molecule, and ZnT8 zinc transporter 8.
† Adjusted hazard ratios were adjusted for the duration of exposure to the study formula.
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